Clinical Trial Update: Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Akt inhibitor MK2206 combined with bendamustine and rituximab in relapsed CLL or small lymphocytic lymphoma has completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• MK-2206 (MK-2206)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-06-28